Recent developments highlight Catalyst Crew Technologies' strategic transition to AI-enabled healthcare, leadership changes, product introductions, and geographic expansion.

• Catalyst Crew Technologies provided an update on its telehealth platform development, indicating ongoing progress in digital health infrastructure [N1].
• The company introduced CardioAI, an AI-driven platform for cardiovascular risk assessment and clinical decision support [N2].
• Catalyst Crew Technologies established an operating presence in Venezuela to support digital health and AI initiatives as part of its Latin American strategy [N3].
• The company introduced an AI-driven healthcare analytics platform to enhance healthcare data analysis capabilities [N4].
• Dr. Kevin Rodan Levy was named CEO as the company advanced its AI-enabled healthcare transformation [N5].
• Catalyst Crew Technologies announced a strategic transition to AI-enabled healthcare and a planned name change to LataMed AI Corp. [N6].

Catalyst Crew Technologies has developed a modular facial recognition technology platform leveraging AI and machine learning, designed for identity verification and analytics in commercial and institutional markets. The company’s focus on privacy, regulatory compliance, and ethical considerations aligns with evolving industry standards. Recent leadership changes and acquisition of AI-enabled healthcare analytics and telehealth assets expand its technology base and market reach, including a strategic presence in Venezuela. The introduction of multiple AI-driven healthcare platforms demonstrates progress in product development and potential for diversified applications. If the company successfully advances development milestones and secures financing, it may establish a foothold in emerging biometric and digital health markets.

Catalyst Crew Technologies remains a development-stage company with no revenue and limited liquidity, as current liabilities exceed current assets. The company’s technology is not yet commercialized, and its progress has been constrained by capital limitations. The facial recognition and AI healthcare sectors are highly competitive, with rapid technological change and significant regulatory and ethical challenges. The company’s dependence on key personnel and majority ownership concentration may pose governance risks. Failure to secure additional financing, complete development milestones, or comply with evolving regulations could impede commercialization efforts and adversely affect business prospects.

Catalyst Crew Technologies operates in a highly competitive and rapidly evolving facial recognition and AI healthcare technology sector. Its moat is currently limited due to its development-stage status, lack of commercial products, and reliance on proprietary software and intellectual property that is still under development. The company’s modular technology architecture and focus on responsible development with privacy and ethical safeguards may provide differentiation. However, the company faces competition from larger, well-capitalized firms with established customer relationships and greater resources. The company’s ability to protect its intellectual property, navigate regulatory environments, and secure financing will be critical to establishing a sustainable competitive advantage.

• Limited Liquidity and Capital Resources: As of December 31, 2025, the company had no current assets and current liabilities of $630,860, resulting in a current ratio of 0. The company depends on external financing to fund development and operations, with substantial doubt about its ability to continue as a going concern without additional capital [S1].
• Development-Stage Status with No Revenue: The company has not generated revenue from its facial recognition technology and remains in the development stage. Its ability to commercialize depends on securing financing, completing development milestones, and regulatory compliance [S1].
• Regulatory, Privacy, and Ethical Challenges: Facial recognition technology is subject to increasing regulatory oversight and privacy laws. The company must address data protection, transparency, and bias mitigation to comply with evolving legal standards. Failure to do so could limit market adoption or expose the company to legal and reputational risks [S1].
• Dependence on Key Personnel and Ownership Concentration: The company’s operations depend heavily on its sole officer and director, who owns a majority of outstanding shares. Loss of this individual or concentration of control may adversely affect business execution and governance [S1].
• Competitive and Rapidly Evolving Industry: The facial recognition and AI healthcare technology markets are characterized by rapid technological change and intense competition from larger, well-capitalized companies. The company’s technology may become obsolete or commercially unattractive if it fails to adapt [S1].
• Risks Related to Technology and Intellectual Property: The company’s software is complex and may contain errors or vulnerabilities. Use of open-source components introduces licensing and security risks. Protection of intellectual property may be insufficient, and infringement claims could be costly [S1].
• Stock Liquidity and Dilution Risks: The company’s common stock is quoted on OTC Markets with limited liquidity and is subject to SEC penny stock rules. Future equity issuances may dilute existing shareholders [S1].

• Catalyst Crew Technologies Corp. is a development-stage technology company focused on research, development, and future commercialization of facial recognition technology (FRT) solutions designed for identity verification, access control, security, and analytics across select commercial and institutional markets [S1].
• The company transitioned its business focus to facial recognition technology in 2024, acquiring related intellectual property and reconstituting its management and board [S1].
• As of December 31, 2025, the company had no full-time employees and relied on independent contractors for technology development and administrative functions [S1].
• The company has not generated revenue from its facial recognition technology operations and remains in the development stage, with activities focused on technology development, product design, strategic planning, and evaluation of commercialization pathways [S1].
• Development efforts in 2025 were limited by capital constraints, focusing on core development, technical architecture, and regulatory, privacy, and ethical considerations [S1].
• The company designs its facial recognition technology with a modular architecture to allow integration with third-party platforms and adaptability to regulatory and customer requirements [S1].
• The technology leverages AI, machine learning, and computer vision to analyze facial images and video data for identification, verification, and analytical purposes, incorporating safeguards for accuracy, privacy, and bias mitigation [S1].
• Target markets include commercial facilities, enterprise environments, and organizations requiring controlled access to physical or digital resources, with intended applications in identity authentication, access control, security monitoring, and data-driven analytics [S1].
• The company is mindful of regulatory, privacy, and ethical considerations related to biometric data, incorporating data protection, transparency, and bias mitigation into development, while monitoring evolving legal standards [S1].
• The company has no commercial products available for sale and has not entered into revenue-producing customer agreements [S1].
• The company’s ability to commercialize depends on securing additional financing, completing development milestones, and complying with regulatory requirements [S1].
• The company’s financial snapshot as of December 31, 2025, shows zero current assets and current liabilities of $630,860, resulting in a current ratio of 0 and cash ratio of 0, indicating limited liquidity [S1].
• The company incurred a net loss of $207,485 for the year ended December 31, 2025, with no revenue generated [S1].
• Diluted earnings per share was -$0.11 for the year ended December 31, 2024 [S1].
• The company’s common stock is quoted on OTC Markets under the symbol CCTC, with limited trading volume and liquidity [S1].
• A change in control occurred in February 2026 when Kevin Rodan Levy acquired a majority stake and was appointed CEO and sole director, leading to resignations of prior executives [S1].
• The company acquired AI-enabled healthcare analytics and telehealth platform assets in February 2026, issuing restricted shares to Dr. Levy as consideration [S1].
• The company established an operating presence in Venezuela through a wholly owned subsidiary as part of its Latin American strategy [N3][S1].
• Recent product introductions include AI-driven healthcare analytics platform, CardioAI for cardiovascular risk assessment, NeuroAI for neurological analysis, PulmoAI for lung disease detection, and telehealth platform development updates [N4][N2][N3][N1].
• The company announced a strategic transition to AI-enabled healthcare and a planned name change to LataMed AI Corp. [N6].
• The company appointed Carlos Peña as Chief Financial Officer in March 2026 [N5].
• The company’s business model is focused on software-based AI and facial recognition technology development with future commercialization plans subject to financing and regulatory approvals [S1].
• The company faces risks including limited liquidity, dependence on key personnel, regulatory and ethical challenges related to biometric data, competitive industry dynamics, and the need for additional financing [S1][S2].